Ascendis Pharma A/S
ASND evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ASND—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ASND
Ascendis Pharma A/S is a biopharmaceutical company applying its TransCon technology platform to develop therapies for endocrine diseases, with approved products YORVIPATH and YUVIWEL and a pipeline in rare endocrine conditions.
Key risk: Financing dependence
BioSniper Score
Based on 6 of 6 signals
Market Cap
$16.26B
Cash Runway
—
Lead Asset
Navepegritide (Phase 2/Phase 3)Next Catalyst
Phase3_Topline · Jun 1, 2028Financial data as of Dec 31, 2025.
Tracking 3 pipeline candidates · 26 clinical trials · 6 catalysts · 3 FDA decisions for Ascendis Pharma A/S.
Similar companies
Ascendis Pharma A/S is a biopharmaceutical company applying its TransCon technology platform to develop therapies for endocrine diseases, with approved products YORVIPATH and YUVIWEL and a pipeline in rare endocrine conditions.
- As of December 31, 2025, Ascendis reported cash and cash equivalents of €616 million ($616.0M) [sec · filed 2026-02-11].
- Total revenue for the year ended December 31, 2025 was $247.5M, with a net loss of $33.6M [latest reported financials].
- The company holds worldwide rights to its TransCon technologies except for certain partnered programs with Eyconis, Novo Nordisk, Teijin, and VISEN [sec · filed 2026-05-07].
- Ascendis discontinued internal development of its oncology program in Q2 2026 to pursue strategic alternatives [sec · filed 2026-05-07].
- The company has a Vision 2030 goal and expects to continue expending substantial resources on R&D and commercialization [sec · filed 2026-02-11].
What works
- Proprietary TransCon platform enables best-in-class potential for therapies addressing unmet medical needs [sec · filed 2026-05-07].
- Approved products YORVIPATH and YUVIWEL provide a revenue base and commercial experience [sec · filed 2026-05-07].
- Strong cash position of €616M as of December 31, 2025 supports operations for at least twelve months [sec · filed 2026-02-11].
- No third-party royalty or milestone payment obligations on core TransCon technologies, except for royalty financing with Royalty Pharma [sec · filed 2026-05-07].
What to weigh
- Significant accumulated losses and reliance on future financing to achieve goals [sec · filed 2026-02-11].
- Substantial dependence on success of a limited number of product candidates, which may fail in trials or commercialization [sec · filed 2026-02-11].
- Clinical development is lengthy and expensive with uncertain outcomes; earlier results may not predict future trial results [sec · filed 2026-02-11].
- Discontinuation of oncology program highlights risk in pipeline prioritization and asset value realization [sec · filed 2026-05-07].
From the filings
Quoted directly from source documents.
Cash position as of December 31, 2025
“As of December 31, 2025, we had cash and cash equivalents totaling €616 million.”
SEC filings · February 11, 2026
Discontinuation of oncology program
“In the second quarter of 2026, we announced our decision to discontinue internal development of our oncology program and to instead pursue strategic alternatives intended to maximize the value of this asset.”
SEC filings · May 7, 2026
Worldwide rights to TransCon technologies
“we hold worldwide rights to our TransCon technologies and, other than our royalty financing arrangements with Royalty Pharma as noted in this report, we owe no third-party royalty or milestone payment obligations with respect to our TransCon technologies”
SEC filings · May 7, 2026
Risks of clinical development
“Clinical drug development involves a lengthy and expensive process with uncertain outcomes, and we may encounter substantial delays in our clinical studies.”
SEC filings · February 11, 2026
Catalyst timeline
- 2028-06-01 · Phase 3 Topline for first pipeline candidate — First pivotal Phase 3 readout for a TransCon product candidate in a rare endocrine condition.
- 2029-03-01 · Phase 3 Topline for second pipeline candidate — Second pivotal Phase 3 readout for another TransCon product candidate.
- 2031-08-01 · Phase 3 Topline for third pipeline candidate — Third Phase 3 readout for a single-arm trial assessing safety and pharmacokinetics.
- 2033-02-27 · YUVIWEL patent/ exclusivity expiry — Loss of market exclusivity for YUVIWEL could open to generic competition.
- 2039-03-01 · Phase 3 Topline for long-term extension trial — Long-term safety and efficacy data from an open-label extension trial.
- 2042-11-12 · YORVIPATH patent/ exclusivity expiry — Loss of market exclusivity for YORVIPATH could open to generic competition.
Risks & what to watch (4)›
Key risks
- Financing dependence — May need additional capital; failure could force delay or cessation of operations [sec · filed 2026-02-11]
- Product concentration — Substantially dependent on success of few products and candidates [sec · filed 2026-02-11]
- Clinical trial uncertainty — Lengthy, expensive trials with unpredictable outcomes; earlier results may not predict later [sec · filed 2026-02-11]
- Commercialization risks — Products may not achieve market acceptance or reimbursement [sec · filed 2026-02-11]
What to watch
- Progress of Phase 3 trials for pipeline candidates, with topline data expected from 2028 to 2039 [upcoming catalysts].
- Execution of strategic alternatives for the discontinued oncology program [sec · filed 2026-05-07].
- Revenue growth from YORVIPATH and YUVIWEL and ability to achieve profitability [sec · filed 2026-02-11].
- Patent expirations for YUVIWEL (2033) and YORVIPATH (2042) and their impact on market exclusivity [upcoming catalysts].
Sources: SEC filings · Generated August 28, 2026 · How we verify sources →
Run Ascendis Pharma A/S through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Ascendis Pharma A/S facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
Profitable (positive operating cash flow)
OCF $73M · Net income -$34M
Lead: Approved
3 candidates
6 upcoming, next in ~641d
9 buys · 1 sell (180d)
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
3
Total value held
$38.4M
| Holder | Shares | Value |
|---|---|---|
| driehaus capital management llc | 127,562 | $29.2M |
| tudor investment corp et al | 38,600 | $8.8M |
| price t rowe associates inc /md/ | 1,530,345 | $350K |
Short Interest
as of May 20, 2026- % of float
- 5.5%
- Days to cover
- 2.7
- Shares short
- 2,832,689
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ASND short interestFrequently asked questions
What is the AI investment thesis for Ascendis Pharma A/S?
Ascendis Pharma A/S is a biopharmaceutical company applying its TransCon technology platform to develop therapies for endocrine diseases, with approved products YORVIPATH and YUVIWEL and a pipeline in rare endocrine conditions.
What is Ascendis Pharma A/S's lead drug candidate?
Ascendis Pharma A/S's most advanced tracked candidate is Navepegritide (Phase 2/Phase 3) for Achondroplasia.
What is Ascendis Pharma A/S's next catalyst?
Ascendis Pharma A/S's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Multicenter, Randomized, Open-Label Trial Investigating the Safety, Tolerability and Effi" — expected June 1, 2028.
Who is the CEO of Ascendis Pharma A/S?
Mr. Jan Moller Mikkelsen is the chief executive officer of Ascendis Pharma A/S (ASND).
Where is Ascendis Pharma A/S headquartered?
Ascendis Pharma A/S (ASND) is headquartered in Hellerup, Denmark.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.